PGNX - Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Foamix Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent to close at 25,998.92, while the S&P 500 Index jumped 0.04 percent to close at 2,888.92. The Nasdaq Composite Index dropped 0.23 percent to close at 7,954.23. Additionally, Apple’s revealing of its new products the iPhone XS, iPhone XS Max and iPhone XR, didn’t trigger an increase in shares.
According to J.J. Kinahan, chief market strategist at TD Ameritrade, “There’s not any great big news to trade on, so it’s likely we’ll primarily be moving on headlines, which means we can be up one hour and then moving down the next.”
“You have to separate a natural selloff from one driven by a real change in the market. It makes sense that we could see some selling after a remarkable year and a half, especially in areas like tech that have done well. But I don’t see a tone change in the market; the numbers continue to point to a strong economy,” Kinahan added, referring to latest market weakness.
RDI Initiates Coverage on:
Progenics Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=PGNX
Foamix Pharmaceuticals Ltd.
https://rdinvesting.com/news/?ticker=FOMX
Progenics Pharmaceuticals’ stock moved 1.62% lower Wednesday, to close the day at $7.30. The stock recorded a trading volume of 649,130 shares, which was below its three months average volume of 1,467,389 shares. In the last year, Progenics Pharmaceuticals' shares have traded in a range of 5.01 - 9.42. The share price has gained 45.71% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.94 is above its 200-day moving average of $7.78. Shares of Progenics Pharmaceuticals have fallen roughly 10.21 percent in the past month and are up 22.69 percent year-to-date.
Access RDI's Progenics Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PGNX
On Wednesday, shares of Foamix Pharmaceuticals recorded a trading volume of 16,451,001 shares, which was above the three months average volume of 152,848 shares. The stock ended the day 3.21% higher at $6.11. The share price has fallen 19.61% from its 52 week high with a 52 week trading range of 4.40 - 7.60. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.80 is above its 200-day moving average of $5.40. Shares of Foamix Pharmaceuticals have gained roughly 6.08 percent in the past month and are up 1.66 percent year-to-date.
Access RDI's Foamix Pharmaceuticals Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=FOMX
Our Actionable Research on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
https://www.accesswire.com/511906/Todays-Research-Reports-on-Trending-Tickers-Progenics-Pharmaceuticals-and-Foamix-Pharmaceuticals